1339191-90-0

Basic information

• Product Name: ethyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide
• Synonyms: ethyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide
• CAS NO: 1339191-90-0
• Molecular Weight: 352.346
• Mol File: 1339191-90-0.mol

Chemical Properties

• CAS DataBase Reference: ethyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide(1339191-90-0)
• EPA Substance Registry System: ethyl 2-benzoyl-3-methylquinoxaline-7-carboxylate 1,4-di-N-oxide(1339191-90-0)

Safety Data

• Hazardous Substances Data: 1339191-90-0(Hazardous Substances Data)

Upstream product

• 39060-33-8 3-oxy-benzo[1,2,5]oxadiazole-5-carboxylic acid ethyl ester 
• 93-91-4 1-phenylbutan-1,3-dione 

Relevant articles and documents

In vitro and in vivo evaluation of quinoxaline 1,4-di-n-oxide against giardia lamblia

Background: Giardiasis is an important public health problem. However, its pharmacological treatment is limited mainly to two drugs, metronidazole and nitazoxanide. Objectives: Screening four series of esters (methyl, ethyl, isopropyl and n-propyl) of quinoxaline-7-carboxylate 1,4-di-N-oxide in in vitro and in vivo models as antigiardiasis agents. Methods: Briefly, 4 × 104 trophozoites of G. lamblia were incubated for 48 h at 37 °C with different concentrations of esters of quinoxaline-7-carboxylate 1,4-di-N-oxide, albendazole, metronidazole and nitazoxanide. Afterwards, trophozoites were counted and the half maximal inhibitory concentration (IC50) was calculated by Probit analysis. The in vivo antigiardial activity of the compounds was demonstrated using experimental infections of G. lamblia in suckling female CD-1 mice. Results: Compound T-069 with a thienyl, a trifluoromethyl and an isopropyl group at R1-, R2-and R3-position, respectively, on the quinoxaline 1,4-di-N-oxide ring in an in vitro model showed an IC50 value of 0.0014 μM, and 3502 and 1108 times more giardicidal activity than nitazoxanide and metronidazole in an in vivo model. Conclusions: Isopropyl ester of quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives showed better giardicidal activity than the reference drugs; therefore, these compounds are good candidates to develop new pharmacological treatment for giardiasis.

Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba histolytica

In our search for new antiamoebic agents, a new series of ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives have been synthesized using the Beirut reaction. All compounds were characterized by spectroscopic techniques and elemental analysis. Antiamoebic activity was evaluated in vitro against Entamoeba histolytica strain HM1:IMSS by the microdilution method, and the structure-activity relationship was analyzed. We found that eleven quinoxaline derivatives showed greater activity than metronidazole and nitazoxanide with IC50 values in the range 1.99-0.35 μM. Compounds T-001 and T-016 shows IC50 values of 1.41 and 1.47 μM, respectively, with a value of selectivity index >60.